| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-06-24 | AGS67E | refractory or relapsed lymphoid malignancies | 1 | Astellas Pharma (Japan) Agensys (USA - CA) | Cancer - Oncology |
| 2014-06-24 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | acute myeloid leukemia (AML) | 2 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-06-24 | SAR408701 | solid tumors | 1-2 | Sanofi (France) | Cancer - Oncology |
| 2014-06-23 | CO-1686 - rociletinib | non-small cell lung cancer |
1-2 | Clovis Oncology (USA - CO) | Cancer- Oncology |
| 2014-06-23 | VRP700 | chronic severe cough in patients with idiopathic pulmonary fibrosis |
2a | Verona Pharma (UK) | Respiratory diseases - Lung diseases |
| 2014-06-23 | Lagova™ ( long-acting CTP-enhanced human growth hormone [hG]) | pediatric growth hormone deficiency disorder |
2 | OPKO Health (USA - FL) | Hormonal diseases - Genetic diseases - Endocrine diseases |
| 2014-06-20 | inecalcitol and azacytidine | acute myeloid leukemia (AML) |
preclinical | Hybrigenics (France) | Cancer - Oncology |
| 2014-06-20 | amyotrophic lateral sclerosis |
preclinical | Kadimastem (Israel) | Neurodegenerative diseases - Rare diseases | |
| 2014-06-19 | undisclosed selective BCL-2 inhibitor | 1 | Servier (France) Vernalis (UK) | Cancer - Oncology | |
| 2014-06-19 | anti-Kv1.3 Nanobody® | preclinical | Ablynx (Belgium) | Inflammatory diseases | |
| 2014-06-19 | naloxegol | non-cancer related pain and opioid-induced constipation |
3 | AstraZeneca (UK) | Digestive diseases - Cancer -Oncology |
| 2014-06-18 | PRX-112 (oral glucocerebrosidase) | Gaucher disease |
2a | Protalix BioTherapeutics (Israel) | Rare diseases - Genetic diseases |
| 2014-06-18 | QGC001 | hypertension | 1 | Quantum Genomics (France) | Cardiovascular diseases |
| 2014-06-17 | Epidiolex® (cannabidiol) | treatment-resistant epilepsy | GW Pharmaceuticals (UK) | CNS diseases - Neurological diseases | |
| 2014-06-17 | enadenotucirev (previously known as ColoAd1) | platinum-resistant ovarian cancer | 2-3 | PsiOxus Therapeutics (UK) | Cancer - Oncology |
| 2014-06-16 | CNV1014802 | trigeminal neuralgia |
2 | Convergence Pharmaceuticals (UK) | CNS diseases |
| 2014-06-16 | Brintellix™ (vortioxetine - Lu AA21004) | major depression |
3 | Lundbeck (Denmark) | CNS diseases - Mental diseases |
| 2014-06-15 | ledipasvir/sofosbuvir fixed-dose combination | genotype 1 hepatitis C |
3 | Gilead (USA) | Infectious diseases |
| 2014-06-14 | Xultophy®/IDegLira® (combination of insulin degludec (Tresiba®) and liraglutide (Victoza®)) | type 2 diabetes |
3a | Novo Nordisk (Denmark) | Metabolic diseases |
| 2014-06-14 | LY2963016 (biosimilar insulin glargine) | type1 diabetes type 2 diabetes |
3 | Boehringer Ingelheim (Germany) Eli Lilly (USA) | Metabolic diseases |
